<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150761</url>
  </required_header>
  <id_info>
    <org_study_id>A00380</org_study_id>
    <nct_id>NCT00150761</nct_id>
  </id_info>
  <brief_title>Facial Thermography Study of Levocetirizine Versus Cetirizine</brief_title>
  <official_title>A Randomized, Double-blind, Double Dummy, Placebo Controlled, Cross-over Exploratory Trial in Healthy Male Adult Subjects: Comparison by Means of Infrared Thermography of the Anti-H1 Potency of Levocetirizine 5 mg and Cetirizine 10 mg Tablet Single Oral Dose After Nasal Histamine Provocation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      Phase IV, human pharmacology, exploratory, randomized, 3-way (3 treatment periods)
      cross-over, double blind, double dummy, placebo controlled study to compare levocetirizine
      and cetirizine by means of IR thermography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare by means of infrared (IR) thermography the anti-histaminic potency of levocetirizine 5mg (single dose) and cetirizine 5mg (single dose) using a placebo as control following 2 nasal histamine provocations (NHP) performed respectively 10 minutes</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess and compare onset of action of levocetirizine 5 mg and cetirizine 10 mg</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore predictive value of screening thermography parameters on treatment effect</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To collect additional safety information on levocetizine</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Anti-allergic Agents</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male Caucasian subject aged between 18 and 55 years (both inclusive).

          -  Subject must have a positive prick test to histamine (wheal diameter ≥ 6 mm with
             histamine dihydrochloride (100 mg/mL) and ≤ 3 mm with diluent control).

        Exclusion Criteria:

          -  History of allergic disease, documented or suspected, including but not limited to:
             asthma, whether or not considered as allergic; nocturnal cough episode suspected to be
             of asthma-equivalent nature (three or more consecutive nights resulting in sleep
             disturbances) ; allergic rhinitis, conjunctivitis or sinusitis; nasal polyposis;
             dermatitis of the face or neck; drug or food allergy.

          -  Any clinically significant vascular disease such as hyper- or hypotension, venous
             disorder, vasculitis etc.

          -  History of hot flushes and any other vasomotor disorders.

          -  ENT infection or Upper Respiratory Tract Infection not completely cured at least one
             week before inclusion.

          -  Any known history of laryngeal edema.

          -  Nasal structural abnormalities (e.g. deviation of the nasal septum…).

          -  Recent immunotherapy

          -  Skin irritants or UV exposure 48 hours before each visit.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/A00380_CSS_20080529.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>August 25, 2014</last_update_submitted>
  <last_update_submitted_qc>August 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2014</last_update_posted>
  <keyword>Nasal histamine provocation, facial thermography, levocetirizine, cetirizine,</keyword>
  <keyword>Xyzal, Zyrtec</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

